Seeking Alpha

Acadia Pharmaceuticals (ACAD) continues to soar, now up over 27% after saying its drug candidate...

Acadia Pharmaceuticals (ACAD) continues to soar, now up over 27% after saying its drug candidate Pimavanserin worked very well reducing hallucinations and delusions related to Parkinson's Disease during Phase III testing.
From other sites
Comments (1)
  • Hulky52
    , contributor
    Comments (15) | Send Message
     
    This is extremely positive news for Acadia for eventually approval of Pimavanserin. Those of us who have significant stock in the company have enjoyed a substantial increase in value since it introduction in the market. I anticipate a multi million world wide market for this drug which offers relief to those suffering from the neurological effects of Parkinson disease .
    21 Mar 2013, 05:38 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs